Arana expands clinical research
Monday, 28 July, 2008
Arana Therapeutics (ASX: AAH) has appointed former Quintiles executive Dr Alan Scott as its new vice president of clinical research.
The Sydney-headquartered biotech, the result of a merger between Peptech and EvoGenix last year, is commencing several new clinical trials in the next 18 months.
Arana's next scheduled clinical trial will be a Phase II rheumatoid arthritis dose-ranging study for its leading anti-inflammatory compound ART621, which is expected to start in the fourth quarter of this year.
Scott holds a PhD from Glasgow University, did a post-doc in biochemistry at Oxford and has held positions in clinical operations and project management in Europe in the pharma, biotech and CRO sectors.
He was director of site start up for Quintiles in the Asia-Pacific region.
Diabetes changes the structure of our hearts, study finds
Type 2 diabetes directly alters the heart's structure and energy systems, which explains why...
Beta blockers could halt triple negative breast cancer
Researchers have identified a molecular biomarker in triple negative breast cancer tumours which...
Common arthritis drug also lowers blood pressure
Scientists have known for a while that methotrexate helps with inflammation, but it may also help...
